24/7 Patient Assistance: 760-405-8205

Mhd Al Marrawi, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information
  • Education & Training

    dept_icon

    Damascus University Faculty of Medicine

    Medical School

    dept_icon

    Reading Hospital Medical Center

    Internship

    dept_icon

    Reading Hospital Medical Center

    Residency

    dept_icon

    Cleveland Clinic Foundation

    Fellowship

  • Board Certifications

    American Board of Internal Medicine - Hematology

    American Board of Internal Medicine - Oncology

  • Publications & Memberships

    Dr. Mhd Al Marrawi has contributed to 3 publications.

    Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

    Al-Marrawi, M. Y.,Saroya, B. S.,Brennan, M. C.,Yang, Z.,Dykes, T. M.,El-Deiry, W. S.; Cancer Biol. Ther.. 2013 Jun 25.

    See more >>

    The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.

    Al-Marrawi, M. Y.,Rini, B. I.,Harshman, L. C.,Bjarnason, G.,Wood, L.,Vaishampayan, U.,Mackenzie, M.,Knox, J. J.,Agarwal, N.,Al-Harbi, H.,Kollmannsberger, C.,Tan, M. H....; Target Oncol. 2013 Sep.

    See more >>

    Pazopanib for the treatment of renal cancer.

    Al-Marrawi, M. Y., Rini, B.; Expert Opin Pharmacother. 2011 May.

    See more >>